SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Reichel H, Koeffler HP, Norman AW 1989 The role of the vitamin D endocrine system in health and disease. N Engl J Med 320: 980991.
  • 2
    Brommage R, DeLuca HF 1985 Evidence that 1,25-dihydroxyvitamin D3 is the physiologically active metabolite of vitamin D3. Endocr Rev 6: 491511.
  • 3
    Reid IR 1996 Vitamin Dits metabolites in the management of osteoporosis. In: MarcusR, FeldmanD, KelseyJ (eds.) Osteoporosis. Academic Press, New York, NY, U.S.A., pp. 11691190.
  • 4
    Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N 1994 Effects of 1-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54: 370376.
  • 5
    Eastell R, Riggs, BL 1997 Vitamin Dosteoporosis. In: FeldmanD, GlorieuxFH, PikeJW (eds.) Vitamin D. Academic Press, New York, NY, U.S.A., pp. 695711.
  • 6
    Baylink D, Stauffer M, Wergedal J, Rich C 1970 Formation, mineralization and resorption of bone in vitamin D-deficient rats. J Clin Invest 49: 11221134.
  • 7
    Tanaka Y, DeLuca HF 1971 Bone mineral mobilization activity of 1,25-dihydroxycholecalciferol, a metabolite of vitamin D. Arch Biochem Biophys 146: 574578.
  • 8
    Weinstein RS, Underwood JL, Hutson MS, DeLuca HF 1984 Bone histomorphometry in vitamin D-deficient rats infused with calcium and phosphorus. Am J Physiol 246: E499E505.
  • 9
    Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345357.
  • 10
    Villanueva AR 1974 A bone stain for osteoid seams in fresh, unembedded, mineralized bone. Stain Technol 49: 18.
  • 11
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2: 595610.
  • 12
    Mosekilde L, Danielsen CC, Knudsen UB 1987 The effect of aging and ovariectomy on the vertebral bone mass and biomechanical properties of mature rats. Bone 14: 16.
  • 13
    Katsumata T, Nakamura T, Ohnishi H, Sakurama T 1995 Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats. J Bone Miner Res 10: 921931.
  • 14
    Raisz LG, Trummel CL, Holick MF, DeLuca HF 1972 1,25-Dihydroxycholecalciferol: A potent stimulator of bone resorption in tissue culture. Science 175: 768769.
  • 15
    Weinsbrode SE, Capen CC, Norman AW 1978 Ultrastructural evaluation of the effects of 1,25-dihydroxyvitamin D3 on bone of thyroparathyroidectomized rats fed on a low-calcium diet. Am J Pathol 92: 459465.
  • 16
    Holtrop ME, Cox KA, Clark MB, Holick MF, Anast CS 1981 1,25-Dihydroxycholecalciferol stimulates osteoclasts in rat bones in the absence of parathyroid hormone. Endocrinology 108: 22932301.
  • 17
    Boyce RW, Weisbrode SE 1985 Histogenesis of hyperosteoidosis in 1,25(OH)2D3-treated rats fed high levels of dietary calcium. Bone 6: 105112.
  • 18
    Wronski TJ, Halloran BP, Bikle DD, Globus RK, Morey-Holton ER 1986 Chronic administration of 1,25-dihydroxyvitamin D3: Increased bone but impaired mineralization. Endocrinology 119: 25802585.
  • 19
    Erben RG, Weiser H, Sinowatz F, Rambeck WA, Zucker H 1992 Vitamin D metabolites prevent vertebral osteopenia in ovariectomized rats. Calcif Tissue Int 50: 228236.
  • 20
    Faugere M-C, Okamoto S, DeLuca HF, Malluche HH 1986 Calcitriol corrects bone loss induced by oophorectomy in rats. Am J Physiol 250: E35E38.
  • 21
    Malluche HH, Faugere MC, Friedler RM, Fanti P 1988 1,25-Dihydroxyvitamin D3 corrects bone loss but suppresses bone remodeling in ovariohysterectomized beagle dogs. Endocrinology 122: 19982006.
  • 22
    Gallagher JC, Jerpbak CM, Jee WSS, Johnson KA, DeLuca HF, Riggs BL 1982 1,25-Dihydroxyvitamin D3: Short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis. Proc Natl Acad Sci USA 79: 33253329.
  • 23
    Need AG, Horowitz M, Philcox JC, Nordin BEC 1985 1,25-Dihydroxycalciferol and calcium therapy in osteoporosis with calcium malabsorption. Miner Electrolyte Metab 11: 3540.
  • 24
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliot R, Colombero A, Scully GES, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165176.
  • 25
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 35973602.
  • 26
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Amgen EST Program, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309319.
  • 27
    Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K 1997 Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234: 137142.
  • 28
    Eastell R 1998 Treatment of postmenopausal osteoporosis. N Engl J Med 338: 736746.
  • 29
    Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E 1999 Rationale for the advantage of alfacalcidol over native vitamin D in the treatment of osteoporosis. Calcif Tissue Int 65: 311316.
  • 30
    Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura A, Cohn SH 1988 Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84: 401408.
  • 31
    Gallagher JC, Goldgar D 1990 Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Intern Med 113: 649655.
  • 32
    Tilyard MW, Spears GFS, Thomson J, Dovey S 1992 Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326: 357362.
  • 33
    Tsurukami H, Nakamura T, Suzuki K, Sato K, Higuchi Y, Nishii Y 1994 A novel synthetic vitamin D analog, 2β-(3-hydroxypropoxy)1α,25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 54: 142149.
  • 34
    Endo K, Katsumata K, Iguchi H, Kubodera N, Teramoto T, Ikeda K, Fujita T, Ogata E 1998 Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia. J Bone Miner Res 13: 13781383.